MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.7 USD | +0.66% |
|
-2.31% | +23.37% |
| May. 09 | Deutsche Bank Raises Moderna's Price Target to $85 From $70 | MT |
| May. 07 | UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.16B | Sales 2025 * | 4.83B | Capitalization | 46.71B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.72B | Net income 2025 * | -1.96B | EV / Sales 2024 * | 9.73 x |
| Net cash position 2024 * | 6.25B | Net cash position 2025 * | 3.94B | EV / Sales 2025 * | 8.85 x |
| P/E ratio 2024 * |
-17.2
x | P/E ratio 2025 * |
-23.6
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
| 1 day | +0.66% | ||
| 1 week | -2.31% | ||
| Current month | +11.22% | ||
| 1 month | +9.94% | ||
| 3 months | +40.36% | ||
| 6 months | +76.51% | ||
| Current year | +23.37% |
1 week
118.68
126.40
1 month
99.30128.81
Current year
84.06128.81
1 year
62.55142.79
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
| Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 121.9 | +0.68% | 2,507,503 |
| 24-05-07 | 121.1 | -0.87% | 2,894,011 |
| 24-05-06 | 122.1 | -2.30% | 3,953,207 |
| 24-05-03 | 125 | -0.47% | 4,513,133 |
| 24-05-02 | 125.6 | +12.68% | 11,973,082 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
121.9
USD
Average target price
138.7
USD
Spread / Average Target
+13.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B | |
| +20.99% | 11.58B |
- Stock Market
- Equities
- MRNA Stock